Beta Drugs Ltd Q2 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Beta Drugs expects to achieve around Rs. 230 crores revenue for the full year, with potential to surpass this after product conversions in January-February (Page 17).
- Company targets 25% to 30% growth annually over the next 3-4 years, driven primarily by oncology portfolio and export markets like LATAM, African, Asian, and CIS regions (Pages 11, 13).
- Exports, especially formulation exports, are major growth drivers; plans to file over 200 dossiers in 2-3 years and expand market presence in regulated and semi-regulated markets (Page 4).
- Cosmetic-Dermatology division aims for Rs. 30-35 crores topline in 3 years, with plans to build a strong brand and own manufacturing plant in 2-3 years (Pages 5, 16).
- CRAMs (contract manufacturing) business is steadily growing with 28-30 customers and addition of new clients expected, contributing progressively to revenues (Pages 16, 17).
See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
- The company discusses internal CAPEX investments, such as Rs. 8.8 crores spent in H1 FY23 mainly for capacity expansion and upgradation, without indicating external fundraising.
- Rahul Batra mentions no major CAPEX requirements for the next 2-3 years until turnover reaches Rs. 400-450 crores, suggesting reliance on internal accruals.
- The company is focusing on growth via expanding exports, CRAMs, and a new Cosmetics/Dermatology division without reference to raising external funds.
- No direct references to plans for debt or equity issuance were made during the call.
See what Beta Drugs Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Beta Drugs has invested around Rs. 4 to 5 crores in scaling up a new API production line, focusing on exports, especially regulated markets (Page 4).
- In April 2022, installed a large Lyophilizer increasing injectable capacity threefold; invested Rs. 1.5 crores on this and Rs. 2.5 crores on upgrading injectable facilities including HVAC system and filter validations (Page 13).
- Rs. 8.8 crores CAPEX incurred in H1 FY23 mainly on Lyophilizer and injectable facility upgrades (Page 13).
- New API production line machinery installation planned to commence by December 2022 (Page 4, 13).
- Land acquired for setting up a new plant for Dermatology and Cosmetology division, with plans to build own manufacturing plant in next 2-3 years (Pages 5, 6).
- No major CAPEX expected for next 2-3 years till turnover reaches Rs. 400-450 crores, leveraging existing capacities (Page 13).
Track Beta Drugs Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Beta Drugs expects revenue growth of 25% to 30% over the next 3-4 years, driven primarily by oncology portfolio and export expansion into LATAM, African, Asian, and CIS markets.
- EBITDA margins for oncology currently exceed 30-35%, with derma/cosmetology segment target margins conservatively at 15-17%, expected to improve to oncology levels once own production commences in 2-3 years.
- Gross margins improved from 37% (H1 last year) to ~42% this year; material cost as percentage of sales reduced from 73% to 68%.
- Receivable days steady around 90-96 days, indicating stable cash cycle.
- Operating cash flow dipped in H1 FY23 due to CAPEX creditor payments but overall financials remain strong.
- CAPEX focus on injectable facility upgrades and new API line to support margin expansion and volume growth.
- Management confident in sustaining strong earnings growth and profitability aligned with revenue trajectory and margin expansion plans.
Order book
Yes- Rahul Batra mentioned expecting a few conversions/orders in January and February which can help surpass the Rs. 230 crore revenue figure for the full year.
- The company currently has clear orders from some good clients in the CRAMs (contract manufacturing) division.
- Agreements for these clients are expected to be finalized by December, with commercial production starting by January or February.
- The CRAMs business has added 3 to 4 new customers this year and plans to add another 3 to 4 in the next year.
- No specific numeric value of the current order book or pending orders was disclosed, but the tone indicates a healthy pipeline with expected growth.
How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?
Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Beta Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…